For example, targeting EGFR with erlotinib (Tarceva, Genentech) induces vascular normalization by reducing the expression of hypoxia-inducible factor-1α (HIF-1α) and VEGF in head and neck squamous cell carcinoma (HNSCC) xenograft models80. The gene discussed is HIF1A; the disease is head and neck squamous cell carcinoma.